Comparison of plasma and urinary microRNA-483-5p for the diagnosis of adrenocortical malignancy

Abel Decmann, Irina Bancos, Aakanksha Khanna, Melinda A. Thomas, Péter Turai, Pál Perge, József Zsolt Pintér, Miklós Tóth, A. Patócs, P. Igaz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Minimally invasive circulating microRNAs might be used for the preoperative differentiation of adrenocortical carcinoma (ACC) and adrenocortical adenoma (ACA). So far, the best blood-borne microRNA biomarker of ACC is circulating hsa-miR-483-5p. The expression of urinary hsa-miR-483-5p as a non-invasive marker of malignancy and its correlation with plasma hsa-miR-483-5p, has not been investigated, yet. Aim: Our aim was to investigate the expression of urinary hsa-miR-483-5p and its correlation with its plasma counterpart. Methods: Plasma and urinary samples from 23 ACC and 23 ACA patients were analysed using real-time RT-qPCR. To evaluate the diagnostic applicability of hsa-miR-483-5p, ROC-analysis was performed. Results: Significant overexpression of hsa-miR-483-5p was observed in carcinoma patients’ plasma samples compared to adenoma patients’ (p < 0.0001, sensitivity: 87%, specificity: 78.3%). In urinary samples, however, no significant difference could be detected between ACC and ACA patients. Conclusions: Plasma hsa-miR-483-5p has been confirmed as significantly overexpressed in adrenocortical cancer patients and thus might be exploited as a minimally invasive preoperative marker of malignancy. The applicability of urinary hsa-miR-483-5p for the diagnosis of adrenocortical malignancy could not be confirmed.

Original languageEnglish
Pages (from-to)49-53
Number of pages5
JournalJournal of Biotechnology
Volume297
DOIs
Publication statusPublished - May 20 2019

Fingerprint

MicroRNAs
Adrenocortical Carcinoma
Plasmas
Adrenocortical Adenoma
Neoplasms
Biomarkers
Adrenal Cortex Neoplasms
Blood
human MIRN483 microRNA
ROC Curve
Adenoma
Carcinoma
Sensitivity and Specificity

Keywords

  • Adrenocortical cancer
  • microRNA
  • miR-483-5p
  • Plasma
  • Urinary

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology

Cite this

Comparison of plasma and urinary microRNA-483-5p for the diagnosis of adrenocortical malignancy. / Decmann, Abel; Bancos, Irina; Khanna, Aakanksha; Thomas, Melinda A.; Turai, Péter; Perge, Pál; Pintér, József Zsolt; Tóth, Miklós; Patócs, A.; Igaz, P.

In: Journal of Biotechnology, Vol. 297, 20.05.2019, p. 49-53.

Research output: Contribution to journalArticle

Decmann, Abel ; Bancos, Irina ; Khanna, Aakanksha ; Thomas, Melinda A. ; Turai, Péter ; Perge, Pál ; Pintér, József Zsolt ; Tóth, Miklós ; Patócs, A. ; Igaz, P. / Comparison of plasma and urinary microRNA-483-5p for the diagnosis of adrenocortical malignancy. In: Journal of Biotechnology. 2019 ; Vol. 297. pp. 49-53.
@article{9050ad7977da468f80eaa0f390befdd1,
title = "Comparison of plasma and urinary microRNA-483-5p for the diagnosis of adrenocortical malignancy",
abstract = "Introduction: Minimally invasive circulating microRNAs might be used for the preoperative differentiation of adrenocortical carcinoma (ACC) and adrenocortical adenoma (ACA). So far, the best blood-borne microRNA biomarker of ACC is circulating hsa-miR-483-5p. The expression of urinary hsa-miR-483-5p as a non-invasive marker of malignancy and its correlation with plasma hsa-miR-483-5p, has not been investigated, yet. Aim: Our aim was to investigate the expression of urinary hsa-miR-483-5p and its correlation with its plasma counterpart. Methods: Plasma and urinary samples from 23 ACC and 23 ACA patients were analysed using real-time RT-qPCR. To evaluate the diagnostic applicability of hsa-miR-483-5p, ROC-analysis was performed. Results: Significant overexpression of hsa-miR-483-5p was observed in carcinoma patients’ plasma samples compared to adenoma patients’ (p < 0.0001, sensitivity: 87{\%}, specificity: 78.3{\%}). In urinary samples, however, no significant difference could be detected between ACC and ACA patients. Conclusions: Plasma hsa-miR-483-5p has been confirmed as significantly overexpressed in adrenocortical cancer patients and thus might be exploited as a minimally invasive preoperative marker of malignancy. The applicability of urinary hsa-miR-483-5p for the diagnosis of adrenocortical malignancy could not be confirmed.",
keywords = "Adrenocortical cancer, microRNA, miR-483-5p, Plasma, Urinary",
author = "Abel Decmann and Irina Bancos and Aakanksha Khanna and Thomas, {Melinda A.} and P{\'e}ter Turai and P{\'a}l Perge and Pint{\'e}r, {J{\'o}zsef Zsolt} and Mikl{\'o}s T{\'o}th and A. Pat{\'o}cs and P. Igaz",
year = "2019",
month = "5",
day = "20",
doi = "10.1016/j.jbiotec.2019.03.017",
language = "English",
volume = "297",
pages = "49--53",
journal = "Journal of Biotechnology",
issn = "0168-1656",
publisher = "Elsevier",

}

TY - JOUR

T1 - Comparison of plasma and urinary microRNA-483-5p for the diagnosis of adrenocortical malignancy

AU - Decmann, Abel

AU - Bancos, Irina

AU - Khanna, Aakanksha

AU - Thomas, Melinda A.

AU - Turai, Péter

AU - Perge, Pál

AU - Pintér, József Zsolt

AU - Tóth, Miklós

AU - Patócs, A.

AU - Igaz, P.

PY - 2019/5/20

Y1 - 2019/5/20

N2 - Introduction: Minimally invasive circulating microRNAs might be used for the preoperative differentiation of adrenocortical carcinoma (ACC) and adrenocortical adenoma (ACA). So far, the best blood-borne microRNA biomarker of ACC is circulating hsa-miR-483-5p. The expression of urinary hsa-miR-483-5p as a non-invasive marker of malignancy and its correlation with plasma hsa-miR-483-5p, has not been investigated, yet. Aim: Our aim was to investigate the expression of urinary hsa-miR-483-5p and its correlation with its plasma counterpart. Methods: Plasma and urinary samples from 23 ACC and 23 ACA patients were analysed using real-time RT-qPCR. To evaluate the diagnostic applicability of hsa-miR-483-5p, ROC-analysis was performed. Results: Significant overexpression of hsa-miR-483-5p was observed in carcinoma patients’ plasma samples compared to adenoma patients’ (p < 0.0001, sensitivity: 87%, specificity: 78.3%). In urinary samples, however, no significant difference could be detected between ACC and ACA patients. Conclusions: Plasma hsa-miR-483-5p has been confirmed as significantly overexpressed in adrenocortical cancer patients and thus might be exploited as a minimally invasive preoperative marker of malignancy. The applicability of urinary hsa-miR-483-5p for the diagnosis of adrenocortical malignancy could not be confirmed.

AB - Introduction: Minimally invasive circulating microRNAs might be used for the preoperative differentiation of adrenocortical carcinoma (ACC) and adrenocortical adenoma (ACA). So far, the best blood-borne microRNA biomarker of ACC is circulating hsa-miR-483-5p. The expression of urinary hsa-miR-483-5p as a non-invasive marker of malignancy and its correlation with plasma hsa-miR-483-5p, has not been investigated, yet. Aim: Our aim was to investigate the expression of urinary hsa-miR-483-5p and its correlation with its plasma counterpart. Methods: Plasma and urinary samples from 23 ACC and 23 ACA patients were analysed using real-time RT-qPCR. To evaluate the diagnostic applicability of hsa-miR-483-5p, ROC-analysis was performed. Results: Significant overexpression of hsa-miR-483-5p was observed in carcinoma patients’ plasma samples compared to adenoma patients’ (p < 0.0001, sensitivity: 87%, specificity: 78.3%). In urinary samples, however, no significant difference could be detected between ACC and ACA patients. Conclusions: Plasma hsa-miR-483-5p has been confirmed as significantly overexpressed in adrenocortical cancer patients and thus might be exploited as a minimally invasive preoperative marker of malignancy. The applicability of urinary hsa-miR-483-5p for the diagnosis of adrenocortical malignancy could not be confirmed.

KW - Adrenocortical cancer

KW - microRNA

KW - miR-483-5p

KW - Plasma

KW - Urinary

UR - http://www.scopus.com/inward/record.url?scp=85063759568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063759568&partnerID=8YFLogxK

U2 - 10.1016/j.jbiotec.2019.03.017

DO - 10.1016/j.jbiotec.2019.03.017

M3 - Article

C2 - 30940435

AN - SCOPUS:85063759568

VL - 297

SP - 49

EP - 53

JO - Journal of Biotechnology

JF - Journal of Biotechnology

SN - 0168-1656

ER -